Open AccessSorafenib is the first targeted agent to treat metastatic kidney cancer
Author(s) -
В. Б. Матвеев,
В. А. Черняев
Publication year - 2015
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2015-1-73-78
Subject(s) - sorafenib , medicine , discontinuation , targeted therapy , oncology , renal cell carcinoma , clinical trial , cancer , drug , pharmacology , hepatocellular carcinoma